We demonstrate a significant increase in anti-tumor activity and overall survival compared to monotherapy alone in CCNE1 amplified OVCA and EMCA PDX models using a low-dosing strategy justifying further evaluation in the clinic (Fig. 3 and Supplementary Fig. S5). This evidence concerns the gene CCNE1 and neoplasm.